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Three-dimensional (3D) printing is a relatively new, rapid manufacturing technology that 
has found promising applications in the drug delivery and medical sectors. Arguably, never 
before has the healthcare industry experienced such a transformative technology. This 
review aims to discuss the state of the art of 3D printing technology in healthcare and drug 
delivery. 
Areas Covered 
The current and future applications of printing technologies within drug delivery and 
medicine have been discussed. The latest innovations in 3D printing of customised medical 
devices, drug-eluting implants and printlets (3D printed tablets) with a tailored dose, shape, 
size and release characteristics have been covered. The review also covers the state of the 
art of 3D printing in healthcare (covering topics such as dentistry, surgical and bioprinting 
of patient-specific organs), as well as the potential of recent innovations, such as 4D 
printing, to shape the future of drug delivery and to improve treatment pathways for 
patients. 
Expert Opinion  
A future perspective is provided on the potential for 3D printing in healthcare, covering 






The healthcare industry is changing rapidly, with the traditional ‘one-size-fits-all’ 
treatment approaches becoming a thing of the past. According to an National Health 
Service (NHS) England report, this conventional treatment pathway involving mass 
manufacture of medicines is ineffective in up to 70% of patients, creating an urgent need 
for new therapies to be personalised to the individual [1]. Traditional manufacturing 
processes are wholly unsuitable for the production of personalised drug delivery therapies, 
involving inherently labour-intensive, dose-inflexible and time-consuming processes. This 
creates a need for the healthcare industry to adapt and embrace new platforms for tailored 
therapy production.  
Three-dimensional (3D) printing, an additive manufacturing technique, is set to become a 
major disruptive technology in healthcare by enabling the production of bespoke objects 
of virtually any shape and size, layer by layer [2]. Structures can be created from a digital 
3D file using computer-aided design (CAD) software or imaging techniques, such as 
magnetic resonance imaging (MRI) or computed tomography (CT) scans, to readily 
manufacture objects that are individualised to each patient [3]. 3D printing processes differ 
from each other in the nature of the material used (e.g. plastics, ceramics, metals, resins), 
technology of deposition, mechanism of formation of the layers or the characteristics of 
the obtained product (e.g. final shape, surface finish, texture, geometrical shape, 
mechanical properties). The American Society for Testing and Materials (ASTM) 
classifies these technologies into seven categories of machines based on the additive 
process involved; namely material extrusion, material jetting, powder bed fusion, binder 
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jetting, vat photopolymerisation, sheet lamination and directed energy deposition (Table 
1).  
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ASTM Category Technologies Substrate Mechanism of Layering 






Solid particles (plastic, 
metal, sand, polymer)  
A liquid binding agent is 
selectively deposited to join 
powder materials  
Vat polymerisation  Stereolithography (SLA) 
Digital light projection (DLP)  
Continuous layer interface 
production (CLIP)  
Liquid (photopolymer)  Liquid photopolymer in a vat 
is selectively cured by light-
activated polymerisation  
Powder bed fusion  Selective laser sintering (SLS)  
Direct metal laser sintering (DLSM)  
Selective metal sintering (SLM)  
Electron beam melting 
(EBM) Concept laser  
Solid particles (metal, 
plastic, polymer)  
Thermal energy selectively 
fuses regions of a powder 
bed  
Material extrusion  Fused deposition modelling (FDM)  
Gel/paste extrusion  
Filament (thermoplastic 
polymers e.g. ABS; PLA; 
PC; ULTEM™ resin)  
Material is selectively 
dispensed through a nozzle 
or an orifice  







Droplets of built material are 
selectively deposited  
Directed energy 
deposition  
Electron beam direct Manufacturing  
Direct metal tooling (DMT)  
Be additive manufacturing (BeAM)  
Wire (metal)  Focused thermal energy is 
used to fuse materials by 
melting as they are being 
deposited  
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Table 1. Classification 
of the main 3D printing 
technologies. ABS = 




Sheet lamination  Laminated object manufacturing  Sheets  Sheets of material are 
bonded to form an object  
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Since the introduction of 3D printing nearly three decades ago, this technology has 
transformed manufacturing in a boundless field of applications. To this day, 3D printing is 
often employed to create engineering prototypes due to its fast production speed and cost-
effectiveness and was in fact first invented for this purpose [4]. Indeed, it seems that the 
applications of 3D printing are limited only by the imagination, with reports of car parts, 
customised fashion accessories, organs and even houses being produced using this 
technology [5,6]. The applications of 3D printing do not stop there. Indeed, 3D printing is 
set to become a revolutionary technology within healthcare; due to its capability to produce 
bespoke and individualised objects, personalised medical prosthetics, implants and devices 
that can be tailored to the individual needs of each patient [7]. In the field of drug delivery, 
various constructs have already been prepared using 3D printing ranging from drug-eluting 
implants, medical devices and personalised solid oral dosage forms [8-14].  
As such, this technology has been explored as a viable method of personalising medicines 
at the point of use and with a view to expand into rapid throughput screening of new drug 
candidates on 3D printed biological tissue to identify intra-individual therapeutic responses 
[15]. 3D printing is competitive for small-scale production of medical devices and drug 
products that require customisation and frequent dosage modification, and for products that 
require complex geometries. Such customisation is not attainable using conventional mass 
manufacturing processes, and has shown a benefit in patient compliance and achieving 
tailored drug release profiles [16,17]. This review will provide a comprehensive overview 
on the most recent advances of 3D printing in healthcare, covering the current and future 
applications in drug delivery and medicine, as well as new innovations and concepts such 
as the impact of 4D printing on drug delivery. 
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2. Applications of 3D Printing 
In medicine, 3D printing offers an advantage limited by other approaches: personalized 
drug delivery systems, prosthetic devices (such implantable defibrillators and equipment) 
and even tissues and organs can be made-to-measure and made-to-order for a specific 
purpose, be that man or machine. The added benefits – cost-effectiveness; simplified 
production techniques; and increased opportunities for collaboration – are equally 
attractive. The current healthcare uses for 3D printing can be characterised into five main 
categories (Figure 1); dentistry, tissue and organ fabrication; anatomical 3D models used 
for surgical training; pharmaceuticals and creating patient specific medical devices (such 
as prosthetics and implants). This section will discuss these existing and future medical 
applications of 3D printing in turn, and its potential to revolutionise manufacturing for this 




Figure 1. Current medical and healthcare applications of 3D printing. SLA = 
stereolithography, SLS = selective laser sintering, FDM = fused deposition modelling, 
DMLS = direct metal laser sintering, SLM = selective laser melting, BJ = binder jetting. 
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Table 2. Examples of the medical applications of 3D printing. FDM = fused deposition modelling, SLA = 
stereolithography, , DLP = direct light processing, SLS = selective laser sintering, BJ = binder jetting, PLA 
= polylactic acid, ABS = acrylonitrile butadiene styrene, PEGDA = polyethylene (glycol) diacrylate, PLGA 
= poly(lactic-co-glycolic acid), PCL = polycaprolactone, TPU = thermoplastic polyurethane, HPMC = 
hydroxypropyl methylcellulose. 
 
Application 3D printing technology Main Polymer composition References 
Scaffold for tissue regeneration FDM PLA, ABS [18] 
Osteochondral scaffolds SLA PEGDA, PLGA [19,20] 
In vivo bone regeneration DLP Vinyl ester, Vinyl carbonate [21] 
Biodegradable scaffolds Inkjet PLGA, Collagen [22,23] 
Scaffolds for tissue regeneration SLS PCL, Gelatine [24,25] 
Implants FDM TPU [26] 
Drug delivery systems  FDM PCL [27] 
Drug-loaded systems Inkjet HPMC [28] 
3D printed pellets for dual-drug therapy SLS Ethyl cellulose, Kollicoat IR [29] 
6-layer polypill for multi-drug therapy SLA PEGDA [30] 
Surgical guides and aids FDM ABS [31] 
Pre-surgical planning Polyjet Photosensitive resin  [32] 
Dental models DLP Photosensitive resin [33] 
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Pre-surgical planning BJ TPU [34] 
Diagnosis and treatment planning Polyjet Acrylic resin [35] 
 
2.1 Dentistry 
To date, 3D printing has been extensively adopted in the field of dentistry for a number of 
applications, ranging from creation of orthodontic surgical models to production of 
replacement teeth [36,37]. As such, 3D printing has been forecast to become a $3.1 billion 
industry in this sector by 2020 [38]. The most widely referred to example of 3D printing in 
dentistry is for the product Invisalign®, which are 3D printed transparent orthodontic 
devices that straighten teeth without the use of traditional metal braces [5].  
 
With the advances of small scanning systems, in the future, instead of patients having 
moulds to be sent to a specialised lab for scanning and retainer production (a process that 
can take weeks), instead a small intraoral camera could be used to scan a patient’s 
misshapen teeth [39]. The digitised scan could then be sent to a local 3D printer for retainer 
production, creating a ‘digital dentistry’ service. 3D printer manufacturers have identified 
the growing need for 3D printers qualified for the production of dentistry parts and hence 
recent developments have been undertaken. As an example, Stratasys have recently 
introduced two specifically designed semi-solid extrusion printers for the purposes of 
dentistry known as CrownWorx
TM and FrameWorx
TM [40]. The printers extrude a form of 
wax designed to allow dental laboratories to create tailor-made crowns and bridges. 
Researchers have also shown the potential of light-curing 3D printing technologies to 
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produce patient-specific dentures with unique antibacterial properties via the inclusion of 
TiO2 within a polymeric resin (polymethyl methacrylate; PMMA) [41]. 
 
Furthermore, recent studies have highlighted the potential for 3D bioprinting to produce 
patient-specific composite tissues for tooth tissue engineering. In particular, the researchers 
developed a fibrin-based bio-ink for printing within human dental pulp stem cells, and 
printing via micro-patterns enabled over 88% viability of stem cells [42].  
 
2.2 Anatomical 3D Models  
There lie multitudinous opportunities for 3D printing applications in surgery ranging from 
the modelling of tumours and other abnormal tissue structures in vitro to inform surgical 
approaches and medical, as well as patient, education [43]. Before the introduction of 3D 
printing, in vitro models were poorly representative of tumour structural complexity and 
crude approximations of tumour microenvironments. More recently, 3D models have been 
used to enable more detailed reconstruction of tumour features from cellular proliferation 
and migration to blood vessel organisation and metastases [44,45]. Rapid prototying of 
such constructions has been widely studied in the cardiovascular, radiology and surgical 
oncology fields, as well as to observe fracture fixations in bone, in turn enabling a better 
planning and preparation of surgical staff before procedures are conducted [46,47]. This 
also feeds in to the use of 3D printing in transplantation. One case study demonstrated the 
use of CT scanning in imaging a paediatric patient’s airway to subsequently generate a 3D 
printed tracheal splint [48]. Indeed, this is a useful area of 3D printing in both modelling 
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and in practical utilisation of models to support surgical intervention namely in the 
generation of splints and guiding templates for resection of bone and other materials, as 
well as suturing devices [49].  
In the same vein, the use of 3D printing has extended to the development of targeted tumour 
therapies, such as in chemotherapy-impregnated mesh devices that can be modelled to 
specifically fit a given tumour that may otherwise be surgically unachievable and which 
previously may have spelt the death knell for affected patients. This has already been 
prototyped in animal models for pancreatic cancer [50] whereby a patient-customised 3D 
printed bioabsorbable implant is targeted to the tumour site and releases drug at constant 
therapeutic levels over a period of 4 weeks. [51].  
2.3. 3D Printing of Oral Drug Products 
  To date, 3D printing has been used to create a range of complex formulations that would 
not easily be produced by conventional manufacturing technologies. This technology 
provides a high flexibility enabling the production of a multitude of drug products with 
tailored release profiles and designs, ranging from controlled-release formulations, fast-
dissolving tablets and multi-drug combinations [11,52-54]. Drug release can be controlled 
by varying three main parameters; namely the printlet geometry, infill percentage and 




Table 3. Latest innovations in dosage form geometry using 3D printing. Reprinted with 
permission from [16,29,30,55]. 
 
 
As an example, several studies have highlighted the ability for drug release to be tailored 
Description Image Reference 
3D printed tablets of cylindrical 
and geometric lattice shapes 





3D printed multi-compartment 
capsular devices for two-pulse 
oral drug delivery 
 
[56] 
3D printed pellets containing 
paracetamol and caffeine (1 and 
2mm) using SLS 
 
[29] 
6 layer polypill in cylindrical and 
ring-shape formations printed 
using SLA technology 
 
[30] 






based on printlet design [57,58]. In one study, printlets were fabricated using SLS with 
cylindrical and gyroid lattice structures and demonstrated the ability to achieve 
customisable release characteristics based on the geometry selected, with lattice structures 
demonstrating faster drug release compared with the cylindrical tablet [16] (Table 3).  
Theophylline-loaded printlets with innovative ‘radiator-like designs’ have also recently 
been developed using FDM printing [55]. Each dosage form had connected paralleled 
plates with inter-plate spacing of either 0.5, 1, 1.5 or 2 mm. The researchers found that the 
minimal spacing between parallel plates of the design should be 1 mm to enable an 
immediate drug release from the structures. 
 
Infill percentage (that is the degree to which the internal space will be filled from 0%, 
hollow, to 100%, solid), has also been found to be another determinant influencing the drug 
release [59]. Previous studies have shown that printlets with a lower infill percentage 
exhibit a faster drug release, whereas tablets with higher infill percentages showed 
extended release profiles [60]. On the contrary, in a study carried out by Chai et al., a 
change in infill percentage was exploited to create gastroretentive tablets [61]. This was 
mainly due to the difference in densities, wherein, tablets having 0–20% infill had a density 
that was lower than that of the fluid media, causing them to float. The buoyancy effect 
increased the residence time of the tablets in the gastric region, promoting drug absorption 
from the early part of the small intestine. However, such phenomenon is highly dependent 
upon a patient’s diet and thus, a high variability in performance is expected.  
Advantageously, certain 3D printing processes (such as SLS and binder jetting [62]) have 
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been found to be capable of formulating highly porous and fast-dissolving tablets [63]. 
This is due to the process loosely binding powder particles together and hence relying 
solely on this weak force to maintain object integrity (instead of mechanical compression 
force). As such, rapidly dispersible tablets can be formulated due to the ease of water 
penetration throughout the formulation matrix. For example, Fina et al. showed, for the 
first time, the application and capability for SLS to produce orodispersible printlets, simply 
by changing the laser speed at which the powder particles were sintered [64]. This dosage 
form demonstrated acceptable pharmacotechnical properties and average disintegration 
times were rapid (<4 seconds). Previous studies have also highlighted the potential for 
binder jet printing to create rapidly-dispersing orodispersible tablets [65]. Indeed, the first 
commercially available application of 3D printing medicines is utilising this unique benefit 
that powder bed printing processes have. By virtue of its binder jet printing manufacturing 
process which forms highly porous tablets, Spritam® is capable of rapidly dissolving in 
the mouth with an average disintegration time of 11 s (ranging from 2 to 27 s), providing 
the intake of a small sip of liquid, even with a high drug load of levetiracetam (up to 1g 
dose per tablet) [66]. 
3D printing has also been shown advantageous in creating amorphous solid dispersions of 
drugs within dosage forms, particularly favourable for enhancing drug release of poorly 
soluble compounds (such as BCS Class II or IV drugs) [10,67,68]. To date, the majority of 
these studies have 3D printed using polymeric materials for stabilisation of drug within the 
matrices. As an example, one study showed the potential for a novel 3D printing 
technology, termed direct powder extrusion, to produce itraconazole-loaded printlets as 
amorphous solid dispersions directly from powdered materials, obviating the need for a the 
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often lengthy development times for filament production required in FDM technology [69]. 
Recent research has also highlighted the capability for 3D printing to create lipid-based 
formulations, (in particular, solid self-microemulsifying drug delivery systems; S-
SMEDDS) to improve drug release of poorly water-soluble drugs [70,71].  
 
Due to the capabilities for precise and flexible spatial distribution of material, 3D printing 
has been widely researched in the production of multi-drug combinations (or polypills). 
Thus far, a number of papers have demonstrated the production of polypills using a range 
of printing technologies [72-74]. For example, Pereira et al. successfully printed a four-
drug cardiovascular polypill [75]. Further to this, 3D printed polypills containing six 
different drugs (paracetamol, naproxen, caffeine, prednisolone, aspirin and 
chloramphenicol) have been printed in multilayer cylindrical and ring-shaped formations 
designed to improve medication adherence for patients on polypharmacy treatment regimes 
[30]. In recent research, Awad et al. demonstrated the ability to produce 3D printed pellets 
(miniprintlets) containing a single drug (paracetamol) and two spatially separated drugs 
(paracetamol and ibuprofen) in 1 mm and 2 mm diameters (Table 2) [29]. By varying the 
polymer, the dual miniprintlets were programmed to achieve customised drug release 
patterns, whereby one drug was released immediately from a Kollicoat IR matrix, whilst 
the effect of the second drug was sustained over an extended time span using ethyl 
cellulose. 
The invention of 3D printed polypills containing spatially-separated compartments is of 
high value, permitting the use of drugs incompatible with one another. In late 2017, a dual 
compartmental oral device was devised for the treatment of tuberculosis containing two 
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drugs which are inherently incompatible (isoniazid and rifampicin) [12]. Separate 
formulations containing isoniazid and rifampicin were inserted into separate 
compartments, preventing the release of the drugs together within the gastric region. Thus, 
it was evident that such approach is beneficial for reducing the interaction caused by this 
combination therapy. Furthermore, the concept of dual compartments can also be utilised 
to target different regions of the gastrointestinal tract.  
The benefits of 3D printing could also have a wide-reaching impact on global health, 
tackling major challenges such as counterfeiting of medicines. It is estimated 10.5% of 
low- and middle-income countries are imposed by substandard or falsified medicines, 
costing an estimated US$ 30.5 billion annually. To overcome this, one study developed a 
unique track-and-trace and anti-counterfeit method, whereby QR codes and smart material 
inks were printed directly on the surface of paracetamol-loaded tablets to ensure product 
authenticity [76]. 
  
2.4. Innovative Medical Devices  
3D printing can also be used to produce bespoke medical devices. To date, designing and 
printing personalised implants and prostheses has become the gold-standard method and 
solution for many patients who require specific constructs. In particular, 3D printing has 
been widely used to fabricate dental parts [77], trauma medical implants and orthopaedic 
medical devices (e.g. knee and hip joint devices) [78]. Unlike other production methods, 
3D printing offers an easy manufacturing method that is less expensive, where the end 
products are tailored specifically for the patient.  
 3D printing has also been used to prepare drug-containing nose masks specifically tailored 
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to the patient for the treatment of acne [79]. In the study, a 3D scanner was utilised to scan 
the patient’s nose and the 3D design was generated which could create a mask that was 
personalised to the patient. This was followed by a similar work conducted by Muwaffak 
et al., where they 3D printed anatomically tailored wound dressings containing zinc, silver 
and copper as their anti-microbial agents in the shape of a nose and an ear [8]. The 
adaptation of masks specific to patients helped in holding the dressings in the wound 
position, gaining further advantage over their analogous flat dressings.  
In other studies, 3D printing has been utilised to create personalised 3D printed intra-
uterine and subcutaneous devices [80,81]. In both studies, results have shown that the drug 
release was faster in the 3D printed devices compared to that from the extruded filaments. 
This was attributed to the presence of the drug in the amorphous form in the 3D printed 
structures, whereas the drug particles in the filaments were in the crystalline form. A 
similar work conducted by Tappa et al. has shown that hormone-eluting intra-uterine 
devices, meshes and rods fabricated using 3D printing could provide an extended activity 
over a period of one week [27]. Furthermore, due to the capability for a precise control 
over material deposition, 3D printing has been used to create patient-specific implants 
[51,82]. Such intricate structures have been found to encourage bone growth and provide 
localised drug therapy, thereby securing the implant firmly in place upon healing. Other 
similar examples include the customisation of 3D printed stents [26], airway splints [83], 
hearing aids [84] surgical meshes containing contrast agents [85] and wearable sensors 
[86]. Such advances of 3D printing can enable better outcomes for patients post-operatively 
and accelerate healing. 
Due to the strict regulations on patients’ health and safety, only a few 3D printed products 
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are currently commercially available, mainly including anatomical surgical guides and 
artificial prosthesis. However, following the approval of Spritam®, the regulatory bodies 
have shown an increased interest in 3D printing. Recently, the FDA has set up an Emerging 
Technology Team (ETT) consisting of a group of pharmaceutical experts to support and 
promote the regulatory evaluation of emerging manufacturing technologies, including 3D 
printing [87]. This was followed by the issuance of a guidance for the ‘Technical 
Considerations for Additive Manufactured Devices” [88]. Thus, more 3D printed drug 
products and medical devices are anticipated to hit the market sooner than expected.  
 
2.5. Bioprinting Tissues and Organs  
There is an increasing demand for the bioprinting of tissues and organs. It is estimated that 
around twenty patients in the U.S.A alone die each day whilst awaiting organ 
transplantation [89], and though still premature as an option for addressing global organ 
donor shortages, 3D printing offers a potential solution nonetheless [90]. Advances in 3D 
printing technology have broached the realm of regenerative medicine, ensuring that the 
printing of biological materials is now very much reality over fantasy. Indeed, such 
bioprinters are capable of printing not only stem cells but of building organs and blood 
vessels in a cell-by-cell fashion, enabling printing of tissues fit for human use on demand 
using automated, laser-calibrated print heads (Figure 2) [91]. Such capacity would not only 
arguably remove the need for cadaveric or live-donor transplants (often at risk of rejection 
owing to tissue or cellular incompatibly with the recipient host alongside prolonged waiting 
lists for human “matches”) but would also potentially allow for elective transplantation of 
 21 
organs in areas such as ageing and regenerative medicine which are both relatively new 
fields of investigation for pre-emptive treatment per se [92].  
 
Figure 2. Pathway for bioprinting of patient-specific tissues and organs for applications in 
transplantation, disease models and drug screening. 
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The U.S.A. stem cell research company Celprogen Inc.® is one such pioneer of 3D organ 
bioprinting having successfully engineered one of the world’s first 3D printed human heart 
that is currently being validated for human use [93]. This was made from polylactic acid 
(PLA) material that was populated with adult human cardiac stem cells. In December 2016, 
Celprogen Inc.® also announced the successful 3D printing of a human pancreas from PLA 
seeded with adult human pancreatic stem cells. The organ was coated with extracellular 
matrix protein and seeded with pancreatic stem cells from two different human lines which 
then successfully differentiated into a functional adult pancreas [94]. Similar to the work 
of Celprogen Inc.®, ETH Zurich have manufactured a silicone heart that is capable of 
beating like the real organ using a lost-wax casting 3D printing technique [95]. Much work, 
however, is required to optimise the silicone 3D printed heart as its current iteration only 
lasts for 3000 beats, sufficient to keep someone alive for 30–45 min. Having said this, this 
work has highlighted the potential for 3D printing to provide a promising solution to the 
lack of organ donations.  
 
3. 4D Printing  
Driven by the disruptive stream of innovative opportunities, the novel concept of four-
dimensional (4D) printing emerged. Built on the conceptual underpinnings of 3D printing, 
the 4D printing method integrates a fourth-dimension; namely time. The printed products 
have the capability to change their configuration (e.g. change in shape, property, or 
functionality) over time. This often occurs in response to an external stimulus, such as heat, 
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light, pH, magnetic or electric forces or moisture. Examples of transformative actions 
include self-assembly, self-dissembling, self-repair or change in colour. Transformation 
into this ‘fourth dimension’ is a result of the feedstock itself (using smart materials) and a 
predetermined 3D design in which the product is created (known as smart design) (Figure 
3).  
 




Smart materials, also known as intelligent or responsive materials, are those that have 
reactive responses, whereby they exhibit a predetermined when exposed to a certain 
stimulus. There are two main types of smart material that have been used in 4D printing 
thus far; (a) hydrogels, which swell when exposed to specific solvents, such as water and 
(b) shape memory polymers (SMPs), which respond to different stimuli, such as 
temperature, pH or UV radiation. In the case of hydrogels, water diffuses into the polymer 
matrix of the fabricated structures inducing swelling and resulting in the change of their 
morphology. Researchers at MIT exploited this concept by printing hinges composed of 
hydrogels to connect rigid hydrophobic structures. Upon exposure to water, the hinges 
swell and bend, producing a 3D cube structure [49]. On the other hand, SMPs are polymers 
that adopt a temporary configuration until exposed to a certain external stimulus, causing 
them recover to their permanent morphology. More specifically, when the smart material 
is introduced to the stimulus, it reaches a critical inflection point, known as its glass 
transition temperature (Tg). At the rested state, the temperature of the polymer is below its 
Tg, meaning it is in its brittle, glassy state. As the temperature elevates above the Tg, the 
polymer transitions into a viscous, more flexible form, known as its rubbery state. This 
makes the material soft and pliable, enabling specific and predetermined changes in its 
structural morphology. Once the temperature falls below the Tg again, the material 
transitions back to its permanent or rested state. Due to their intricate structures, it is often 
difficult and time-consuming to produce stents using conventional manufacturing 
approaches. Favourably, owing to their transformative properties, SMPs have been widely 
applied for the fabrication of dynamic stents that are able to contort when exposed to the 
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body temperature after insertion into a patient [96]. As such, using 4D printing, stents of 
any size and shape can be produced in a time and cost-efficient manner. Interestingly, the 
use of multiple smart approaches could provide synergistic effects. An example of such are 
3D printed stents composed of iron oxide, a material that responds to magnets, combined 
with a PLA-based ink having thermo-responsive properties. Unlike conventional stents, 
these smart structures have the combined benefits of being personalised for each individual 
patient while having the ability to be controlled remotely [97,98]. 
In addition to being composed of smart materials, the programming of 4D printed objects 
is dependent upon the 3D design of the object. More specifically, to induce predetermined 
morphological changes, the structure and the orientation of the smart materials within the 
object should be considered carefully [96]. In simpler terms, 4D printing essentially is 
based on the 3D printing of smart materials to create dynamic structures with the ability to 
self-fold or unfold. It is important to note that many of these smart materials have already 
previously been applied to pharmaceutics and drug delivery. Although they were not used 
for 3D printing, it is still possible to predict their likely applications within 4D printing. 
Based upon their drug delivery mechanisms, we can classify objects made using smart 
materials into two categories; bio-adhesive and encapsulation devices.  
Bio-adhesive devices are drug delivery systems that induce drug release by affixing to the 
intestinal endothelium. An example of such includes a tri-layered, muco-adhesive device 
composed of an outer pH sensitive hydrogel. Once in the small intestine (pH = 6.5), the 
device contorts and grips onto the intestinal wall. The gripping mechanism increases the 
intestinal residence time of the devices, allowing more drug to diffuse into mucosal 
epithelium [99]. A similar approach includes the ‘theragrippers’, which are thermo-
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responsive eluting devices, characterised for having multiple arms [100]. These devices are 
programmed to spontaneously grip and affix onto tissue once subjected to temperatures 
above 32°C. Advantageously, due to their high porosity, the structures could be loaded 
with high amounts of drug, which in turn provides a constant drug release up to 7 days. 
Building upon this concept, the incorporation of iron oxide nanoparticles into the porous 
hydrogel layer provides an added magnetic responsive feature, via which the devices could 
be remotely transported to their target site within a clinical setting or during surgery or 
even used as surgical tools themselves [101].  
Encapsulation devices on the other hand, are self-assembling structures that fold into closed 
containers in which different materials, such as fibroblasts, pancreatic beta cells and yeast 
cells [102], could be contained [103]. Unlike conventional dosage forms, these smart 
devices are programmed to release their contents when exposed to predetermined 
temperatures [104]. An example of this system includes bilayer micro-robots, consisting 
of a pH-responsive layer and an iron oxide-based layer, which were fabricated by 
conventional lithography for anticancer therapy [105]. The dual mechanism consists of the 
use of a magnetic force to remotely guide the micro-robots to the tumour site, after which 
they are activated by the acidic nature of the tumour tissue (pH = 4.5–6.0), causing them 
to release their contents and provide targeted therapy, reducing the cell viability by 70% 
whilst limiting the amount of drug that passes throughout the systemic circulation.  
 
Due to its novelty, 4D printing as a concept has minimally applied to pharmaceutical 
formulation. Recently, Melocchi et al. have explored this concept to fabricate retentive 
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devices for the intravesical delivery of medicines [106]. They utilised SMPs that were 
programmed to hold a temporary conformation allowing administration into the bladder. 
Once in contact with water, the devices transform back into their permanent shapes, 
permitting them to be retained in the bladder (Figure 4). The increase in the intravesical 
residence time could enhance the efficiency of treatment by providing prolonged, localised 
drug delivery. Although still primitive, the use of 4D printing within pharmaceutics could 
reinvigorate the concepts of drug delivery, making it possible to create medications that 
were previously challenging to produce. 
 
Figure 4. Images outlining the shape memory properties (at room temperature) of the intravesical 
devices having an original I- and U-shape fabricated by FDM 3D printing. A solid line is 
superimposed to highlight the recovery process. (Reprinted with permission from [106]) 
 
5. Benefits and Challenges of 3D Printing in Drug Delivery and Medicine  
The benefits of 3D printing also range far beyond its ability to be personalised. Financially, 
3D printing offers a competitive alternative to smaller-scale production costs; one example 
being NASA who utilised 3D printing to produce a rocket fuel injector at a third of the cost 
previously via traditional manufacturing approaches. Other areas of cost-effectiveness 
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extend to areas such as the pharmaceutical industry whereby customisation of specific 
drugs may enable dose and cost reduction depending on intra-individual profiling for 
therapeutic dosing and equally in the rapid rate of production of on-demand objects and 
devices versus multiple-process manufacture in industry or otherwise. This has been 
exemplified in the generation of 3D printed in vitro models considered easier to image, 
manipulate and process at a higher throughput compared to in vivo models. Another 
important benefit of 3D printing and specifically in medicine as well as other fields, is in 
collaboration and data sharing – a pioneer of this being the National Institutes of Health 
(NIH), who founded the shared 3D printing data network 3D Print Exchange. Initially used 
in-house where 3D printers are available throughout the institute’s campus for data sharing 
of software and images for 3D printing, this is now an open-access resource enabling all 
users to share 3D print files for various devices.  
Although 3D printing offers promising applications and capabilities within the field of 
medicine, an important obstacle to consider is the feasibility of use in a clinical setting. As 
with the advent of any other avant-garde technology, and as is especially the case in 
medicine, regulatory requirements and limitations also apply to the constantly-evolving 
field of 3D printing, rendering the development of new applications within both an 
ethically and safety-specific grey area. Whilst printing speeds, processing speeds and 
resolutions have significantly advanced over the past few years with respect to 3D printing, 
these parameters have lagged behind the optimal levels often employed for scale-up 
manufacturing techniques. However, more recently, the FDA have developed a draft 
guidance to promote the technical considerations specific to devices using additive 
manufacturing which is promising for the scope of 3D manufacturing [107].  
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The potential for 3D printing as a solution to personalisation as well as on-demand 
generation of surgical and medical equipment is an exciting and very real one, aside from 
its other potential in the personalisation and on-demand printing of medicines and medical 
devices for individual patient use be that via handheld 3D printing devices, use of in situ 
printing approaches with precise dimensional specifications, or large-scale 3D printing 
manufacture. Others have postulated that harnessing stem cells at birth or in early life could 
even allow for bioprinting of regenerative tissues via the medium of 3D printing.  
 
6. Conclusion 
Though 3D printing is still in its infancy within the pharmaceutical sector, the transition to 
4D might occur beforehand. The use of ‘smart drugs’ can provide a more targeted therapy 
that can be personalised for the necessities of each individual patient, initiating a digital 
revolution within drug delivery and healthcare. Whether this is ultimately adopted as such 
an approach remains to be seen, though the ever-growing research and non-expert 
utilisation of such drug delivery systems would suggest in favour. Nonetheless, as the FDA 
supports the development of complex dosage forms and the use of innovative 
manufacturing approaches using science and risk-based approaches, this may accelerate 
the adoption of such innovative technologies within healthcare. Currently, technical and 
quality control limitations are the dominant constraints that hinder the adoption of 3D 
printing. It is anticipated that once an ideal printing platform is established, it will be a 
matter of time before 3D printers takeover pharmaceutical shelves, commencing a new era 
of digital health. 
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7. Expert Opinion 
Whilst technological improvements are constantly being made insofar as this notion is 
concerned, preliminary results appear promising. In particular, it is foreseen that 3D 
printing is well suited to be used within digital health domains, changing the face of 
pharmaceutical manufacture. A favourable aspect would include its adoption by the 
pharmaceutical industry as a feasible alternative to current fabrication methods. However, 
many would argue that this technology is still primitive and its goal is not to replace mass 
production but to complement it for instance, in the production of complex dosage regimes 
of drugs with narrow therapeutic indices, where accurate dosing is needed to maintain 
treatment efficacy and patient safety, or biological products, which are often unstable under 
storage conditions. Alternatively, 3D printing could be leveraged for the production of on-
demand dosage forms tailored to the needs of challenging patient subgroups, such as young 
children and the elderly, where dosing requirements can be markedly different when 
compared with adults.  
By integrating a 4th dimension such as time, it possible to achieve dynamic structures with 
programmable shapes, properties, or functionality. The use of novel strategies such as 4D 
printing is advantageous within the pharmaceutical sector, especially for the advancement 
of controlled drug delivery. By evaluating smart materials currently applied in 
pharmaceutical formulation, the initial applications and beneficial attributes of 4D printing 
can be unveiled. For instance, by applying 4D printing to produce structures of high 
resolution and complexity, not only would the process improve in terms of time and cost 
efficiency, but also the opportunity for bespoke treatments emerges. Within pharmaceutics, 
the most valuable purpose of this process is the fabrication of engineered drug delivery 
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devices for targeted therapies. This could be achieved by utilising pH as a stimulus, 
permitting the affixation of formulations to specific regions in the gastrointestinal tract. In 
turn, the use of such smart systems provides superior drug absorption within the site of 
action, improving the efficacy of treatment.  
 
It is clear that the integration of 3D printing into clinical practice could pave the way for a 
digital health revolution, changing the way medicines are designed and prescribed for 
patients. However, the healthcare sector is known for being notoriously resilient to change, 
owing to the presence of regulatory guidelines and clinical standards, both of which pose 
technical and quality control challenges. Though such regulations promote patient safety, 
they are often a stumbling block in the route of modern technological advancements. 
Indeed, as the evidence-base for 3D printing continues to grow, it is becoming evident that 
action is required to translate the theoretical benefits of 3D printing into real-world benefits 
for patients.  
To date, a limited number of in vivo studies have been carried out albeit with highly 
promising results. In 2017, the first in vivo acceptability study was performed using 
whereby 3D printed dosage forms were designed to have a variety of different shapes and 
sizes, which were evaluated for ease of swallowing and handling in human volunteers [17]. 
Novel diamond shape structures were designed to be structurally raised enabling an ease 
of handling in patients with dexterity challenges. In terms of swallowing, patients were 
found to prefer the torus, cylinder and oblong shapes, demonstrating how different 3D 
printing geometries could be used to improve medication acceptability. Following on from 
this work, Liang. et al. undertook a first-in-human study of a 3D printed wearable oral-
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drug delivery device in the form of a mouthguard, designed to have tunable drug release 
rates [108]. University College London (UCL) in partnership with FabRx, a company 
focussing on using 3D printing for personalised medicines and devices, have also recently 
performed a world first clinical study whereby a 3D printer was integrated into a hospital 
pharmacy for personalised treatment of children with a rare metabolic disease [109]. Such 
advancements demonstrate the revolutionary potential of 3D printing however further 
studies are required in order to progress this technology away from an academic concept 
towards real-world benefits for patients. 
Currently, commercial 3D printers do not abide by Good Manufacturing Practice (GMP) 
requirements. As such, regulating their use to produce solid oral dosage forms in a clinical 
setting, e.g. local pharmacy or hospital remains an unmet need. In addition, all aspects of 
the printing process would require thorough evaluation to confirm that the final dosage 
forms are uniform. In fact, the use of multiple production sites adds further technical and 
logistic challenges, wherein it is difficult to ensure that the end-products are of consistent 
quality, due to the multiple variables affecting the process including different settings, 
hardware, raw material suppliers and operator training [3]. Thus, this instigates the need 
for quality control (QC) measurements, such as the use of non-destructive characterisation 
methods, including process analytical technologies (PAT), such as near-infrared (NIR) 
spectroscopy [10,110,111], Raman spectroscopy [76,112,113] or colourimetry [114,115], 
to monitor drug performance and ensure requirements imposed by regulatory bodies are 
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